A5012389975- Diabetes Management and Research
- Rheumatoid Arthritis Research and Therapies
- Diabetes Treatment and Management
- Autoimmune and Inflammatory Disorders Research
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Biosimilars and Bioanalytical Methods
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Spondyloarthritis Studies and Treatments
- Psoriasis: Treatment and Pathogenesis
- Diabetes and associated disorders
- Adolescent and Pediatric Healthcare
- Dermatology and Skin Diseases
- Lymphoma Diagnosis and Treatment
- Neurological and metabolic disorders
- Healthcare Systems and Practices
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Health, Medicine and Society
- Pancreatic function and diabetes
- Health Systems, Economic Evaluations, Quality of Life
- Tuberculosis Research and Epidemiology
- Parkinson's Disease Mechanisms and Treatments
- Colorectal Cancer Screening and Detection
- Radiomics and Machine Learning in Medical Imaging
- Peripheral Neuropathies and Disorders
- Diagnosis and treatment of tuberculosis
Pfizer (France)
2020-2024
Institut thématique Immunologie, inflammation, infectiologie et microbiologie
2021-2023
Background: Current treatments for PsA have proven effective in reducing patient (pt)-reported pain; 1,2 however, residual pain often remains. Tofacitinib is an oral Janus kinase inhibitor the treatment of PsA. Objectives: This descriptive analysis evaluated effect tofacitinib, adalimumab and placebo on pts with whose inflammation was attenuated after 3 months therapy. Methods: Data were included from OPAL Broaden ( NCT01877668 ), a randomised, double-blind, placebo-controlled Phase trial 12...
Objective Post hoc analysis of pooled data from nine randomised controlled trials to assess the effect tofacitinib (oral Janus kinase inhibitor for treatment rheumatoid arthritis (RA) and psoriatic (PsA)) on residual pain in patients with RA or PsA abrogated inflammation. Methods Patients who received ≥1 dose 5 mg twice daily, adalimumab placebo with/without background conventional synthetic disease-modifying antirheumatic drugs had inflammation (swollen joint count (SJC)=0 C reactive...
The global coronavirus 2019 (COVID-19) pandemic created many challenges in healthcare provision. This study aimed to evaluate the impact of COVID-19 on people living with rheumatoid arthritis (RA). RA Narrative survey was conducted online among who resided Brazil, Canada, France, Japan, and US from August September 2021. examined disease management, access experiences, participant preferences for interactions their doctor. Overall, 500 participants completed survey: 100 each US. Emotional...
We evaluated the impact of gender on disease severity, health-related quality life (HRQoL), treatment management, and patient–healthcare professional (HCP) interactions from perspectives patients with psoriatic arthritis (PsA). Data were collected a global online patient survey conducted by The Harris Poll (November 2, 2017 to March 12, 2018). Eligible aged ≥ 18 years, self-reported diagnosis PsA for > 1 year, had visited rheumatologist/dermatologist in past 12 months, reported previously...
<h3>Background</h3> Patients with IMID, and notably patients rheumatoid arthritis RA, are at increased risk of cancer compared the general population [1,2]. It is hence paramount to assess impact biological or targeted DMARD (e.g.., tofacitinib TNFi) on outcome in already at-risk, particularly context ORAL Surveillance which showed a higher for malignancies (excluding nonmelanoma skin cancer, NMSC) tofacitinib, comparison TNFI, RA [3]. <h3>Objectives</h3> To TNFi treated real-world clinical...
To compare perceptions of disease control and treatment satisfaction between patients with psoriatic arthritis (PsA) in North America Europe, participating countries within each region.Data were collected from self-reported PsA diagnoses using an online survey. Results questions on overall health, severity, symptoms, impacts, satisfaction/preferences reported descriptive statistics Chi-square tests.A total 456 (Canada, n = 155; US, 301) 417 Europe (France, 123; Spain, 135; UK, 159) included...
Background Tofacitinib, an oral Janus Kinase inhibitor, is indicated in the treatment of adult patients (pts) with active, moderate to severe rheumatoid arthritis (RA). At present time we have no data concerning its efficacy a French RA population real-life setting. Objectives DeFacTo, on-going observational study principal goal which identify factors predictive Tofacitinib drug survival real life. Methods These are results interim descriptive analyses effectiveness after 1 year follow up....
<h3>Background</h3> Residual pain often remains in patients (pts) with rheumatoid arthritis (RA) and psoriatic (PsA) who achieve low disease activity or remission.<sup>1,2</sup> Tofacitinib is an oral JAK inhibitor for the treatment of RA PsA. A descriptive analysis showed that tofacitinib may have a beneficial effect on residual pts PsA abrogated inflammation.<sup>3</sup> <h3>Objectives</h3> To assess efficacy tofacitinib, adalimumab (ADA) placebo (PBO) inflammation, using network...
Background: Tofacitinib is an oral JAK inhibitor indicated for moderate to severe active rheumatoid arthritis (RA). Objectives: To present baseline patients characteristics and effectiveness data at 6 months of DeFacTo real life study (“I De ntification Fa ctors predictive facitinib’s survival”). Methods: observational, open-label, prospective, multi-center, national designed evaluate the factors tofacitinib’s survival in with moderate-to-severe according SmPC [1] . Here we 1st interim...
<h3>Background</h3> Women with psoriatic arthritis (PsA) have more severe disease activity and lower health-related quality of life vs men.<sup>[1]</sup> <h3>Objectives</h3> To assess sex differences in impact perceptions physician interactions patients (pts) PsA using global survey data. <h3>Methods</h3> An online by The Harris Poll (2 Nov 2017–12 Mar 2018) included 1286 pts from 8 countries, aged ≥18 years, who had for >1 year, visited a rheumatologist/dermatologist the past 12 months...
<h3>Background</h3> Patients with IMID, and notably patients rheumatoid arthritis (RA), are at increased risk of major adverse cardiovascular event (MACE) compared the general population [1,2]. It is hence paramount to assess impact biological or targeted DMARD (e.g., tofacitinib TNFi) on MACE in already at-risk, particularly context ORAL Surveillance which showed a higher tofacitinib, comparison TNFI, RA [3]. <h3>Objectives</h3> To TNFi treated real-world clinical practice. <h3>Methods</h3>...
<h3>Background</h3> Tofacitinib, an oral JAK inhibitor, is indicated for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA) which we have no real-life effectiveness data in a French RA population. <h3>Objectives</h3> To describe tofacitinib profile according concomitant use csDMARD prospective observational study, DeFacTo. <h3>Methods</h3> DeFacTo, ongoing study primary objective identifying predictive factors Tofacitinib maintenance patients. The...